Chugai Pharmaceutical Co Ltd
4519: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥2,294.00 | Byqxbkp | Mqfdddhw |
Chugai Earnings: Results In Line, Mixed Pipeline Updates, Shares Now Close to Fair Value
Narrow-moat Chugai’s second-quarter earnings were in line with expectations. We think the company is on track to meet its full-year guidance or even outperform slightly, due to strong sales of Hemlibra to Roche. We maintain our fair value estimate of JPY 4,860. Shares have rallied about 20% since May and are now at an 8% discount to our fair value.